SEC Form SC 13G/A filed by INVO BioScience Inc. (Amendment)

9/8/23 4:34:56 PM ET

Medical/Dental Instruments

Health Care

Get the next $INVO alert in real time by email

SC 13G/A 1 invo13g090823t.txt INVO 13G/A THE UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4)* INVO Bioscience, Inc. (Name of Issuer) Common Stock, Par Value $0.0001 (Title of Class of Securities) 44984F302 (CUSIP Number) August 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule 13G is filed: [X] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) *The remainder of this cover page shall be filled out for a reporting person?s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be filed for the purpose of Section 18 of the Securities Exchange Act of 1934 (Act) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). CUSIP No. 44984F302 (1) Names of Reporting Persons. I.R.S. Identification Nos. of Above Persons (entities only): AWM Investment Company, Inc. (2) Check the Appropriate Box if a Member of a Group (See Instructions) (a)___ b)___ (3) SEC Use Only (4) Citizenship or Place of Organization: Delaware, United States Number of Shares Beneficially Owned by Each Reporting Person With (5) Sole Voting Power: 63,193** (6) Shared Voting Power: 0** (7) Sole Dispositive Power: 63,193** (8) Shared Dispositive Power: 0** (9) Aggregate Amount Beneficially Owned by Each Reporting Person: 63,193** (10) Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions): (11) Percent of Class Represented by Amount in Row (9): 2.6%** (12) Type of Reporting Person (See Instructions): IA **AWM Investment Company, Inc., a Delaware corporation (AWM), is the investment adviser to Special Situations Life Sciences Fund, L.P. (SSLS). (SSLS will hereafter be referred to as the Fund). As the investment adviser to the Fund, AWM holds sole voting and investment power over 63,193 shares of Common Stock of the Issuer (the Shares) held by SSLS. See Items 2 and 4 of this Schedule for additional information. Item 1(a). Name Of Issuer: INVO Bioscience, Inc. Item 1(b). Address of Issuer?s Principal Executive Offices: 5582 Broadcast Court Sarasota, Florida 34240 Item 2(a). Name of Person Filing: The person filing this report is AWM Investment Company, Inc., a Delaware Corporation (AWM), which is the investment adviser to Special Situations Life Sciences Fund, L.P., a Delaware limited partnership (SSLS), (SSLS, will hereafter be referred to as the Fund) The principal business of the Fund is to invest in equity and equity-related securities and other securities of any kind or nature. David M. Greenhouse (Greenhouse) and Adam C. Stettner (Stettner) are members of LS Advisers, L.LC., a New York limited liability company (LS). Greenhouse and Stettner are also controlling principals of AWM. Item 2(b). Address of Principal Business Office or, if None, Residence: The principal business address for AWM is c/o Special Situations Funds, 527 Madison Avenue, Suite 2600, New York, NY 10022. Item 2(c). Citizenship: AWM is a Delaware Corporation. Item 2(d). Title of Class of Securities: Common Stock, Par Value $.0001 Item 2(e). CUSIP No.: 44984F302 Item 3. If This Statement Is Filed Pursuant to ??240.13d-1(b) or 240.13d-2(b) or (c), check whether the Person Filing is a: Not Applicable. Item 4. Ownership (a) Amount Beneficially Owned: 63,193** (b) Percent of Class: 2.6%** (c) Number of Shares as to which the person has: (i) sole power to vote or to direct the vote: 63,193** (ii) shared power to vote or to direct the vote: 0** (iii) sole power to dispose or to direct the disposition of: 63,193** (iv) shared power to dispose or to direct the disposition of: 0** ______________________________________________________________________ **AWM Investment Company, Inc., a Delaware corporation (AWM), is the investment adviser to Special Situations Life Sciences Fund, L.P. (SSLS). (SSLS will hereafter be referred to as the Fund). As the investment adviser to the Fund, AWM holds sole voting and investment power over 63,193 shares of Common Stock of the Issuer (the Shares) held by SSLS. Greenhouse and Stettner are members of MGP, the general partner of SSFQP; an LS, the general partner of SSLS. Greenhouse and Stettner are also controlling principals of AWM. Item 5. Ownership of Five Percent or Less of a Class If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following. _X__ Item 6. Ownership of More Than Five Percent on Behalf of Another Person Not Applicable. Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person Not Applicable. Item 8. Identification and Classification of Members of the Group Not Applicable. Item 9. Notice of Dissolution of Group Not Applicable. Item 10. Certification By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. SIGNATURE After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Dated: September 8, 2023 AWM INVESTMENT COMPANY, INC. By: /s/ Adam Stettner Name: Adam Stettner Title: Executive Vice President Attention: Intentional misstatements or omissions of fact constitute Federal criminal violations (See 18 U.S.C. 1001) -1-

Get the next $INVO alert in real time by email

Date

Price Target

Rating

Analyst

1/19/2022

$7.00

Buy

Maxim Group

8/18/2021

$5.75 → $5.25

Buy

Roth Capital

SEC Form SC 13G/A filed by INVO BioScience Inc. (Amendment)

Chat with this insight

Recent Analyst Ratings for
$INVO

$INVO
Press Releases

Fastest customizable press release news feed in the world

NAYA Biosciences Announces Initiation of Phase 1/2a Clinical Trial for its GPC3-targeted NK Engager Bispecific Antibody in Patients with Hepatocellular Carcinoma

INVO Bioscience Confirms Corporate Name Change and New Trading Symbol in Connection with Its Recent Merger with NAYA Biosciences

INVO Bioscience and NAYA Biosciences Close Merger, Combined Company to Operate as NAYA Biosciences (NASDAQ: NAYA)

$INVO
SEC Filings

SEC Form RW filed by INVO BioScience Inc.

INVO BioScience Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits

$INVO
Financials

Live finance-specific insights

INVO Reports Record Third Quarter 2023 Financial Results

INVO to Report Second Quarter 2023 Financial Results on Monday, August 14, 2023

INVO Bioscience to Report First Quarter 2023 Financial Results on Monday, May 15, 2023

$INVO
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Maxim Group initiated coverage on INVO Bioscience with a new price target

Roth Capital reiterated coverage on INVO Bioscience with a new price target

$INVO
Large Ownership Changes

This live feed shows all institutional transactions in real time.